NCT02528383View on ClinicalTrials.gov

Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors

NACompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Breast Cancer
Interventions
BEHAVIORAL

Vagifem

"Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:~1. Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.~2. Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.~3. Impact of treatment on quality of life"

Trial Locations (1)

06032

UConn Health, Farmington

All Listed Sponsors
collaborator

Connecticut Breast Health Initiative

OTHER

lead

Susan Tannenbaum

OTHER

NCT02528383 - Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors | Biotech Hunter | Biotech Hunter